GlassScriptPhysician profile
Douglas A Witter
NPI 1437107257
$5,994.46
in general payments reported to CMS, 2019-2025
40 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $270 · 2021: $1,057 · 2022: $1,207 · 2023: $1,486 · 2024: $1,554 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $809.14 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $657.84 | 2020-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $633.95 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $481.92 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $444.03 | 2021-2025 | |
| Abbott Laboratories | $424.13 | 2021-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Lilly USA, LLC | $401.33 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $377.71 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $319.42 | 2020-2025 | Nexletol |
| Amgen INC. | $203.56 | 2020-2025 | Repatha, Otezla, Prolia |
| Astellas Pharma US INC | $157.14 | 2023-2025 | Veozah, Myrbetriq |
| Amneal Pharmaceuticals LLC | $91.64 | 2021-2023 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $85.19 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.11 | 2022-2024 | |
| Amarin Pharma, INC. | $70.85 | 2020-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Witter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.